Cara Therapeutics, Inc.

NasdaqCM:CARA Stok Raporu

Piyasa değeri: US$16.3m

Cara Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Cara Therapeutics CEO'su Chris Posner, Nov2021 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 2.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.9% maaş ve 75.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.21% ine doğrudan sahiptir ve bu hisseler $ 34.17K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 5.3 yıldır.

Anahtar bilgiler

Chris Posner

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi24.9%
CEO görev süresi3yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi3yrs
Yönetim Kurulu ortalama görev süresi5.3yrs

Son yönetim güncellemeleri

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Nov 01
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Share Price Is Matching Sentiment Around Its Revenues

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jul 18
Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29
We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

May 25
Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19
The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04
News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20
Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04
Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11
News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15
Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06
We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18
We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15
We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12
Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09
Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15
The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive

Jul 19

CEO Tazminat Analizi

Chris Posner'un ücretlendirmesi Cara Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$123m

Dec 31 2023US$3mUS$728k

-US$119m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$112m

Mar 31 2023n/an/a

-US$84m

Dec 31 2022US$3mUS$700k

-US$85m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$93m

Dec 31 2021US$10mUS$116k

-US$88m

Sep 30 2021n/an/a

US$24m

Jun 30 2021n/an/a

US$8m

Mar 31 2021n/an/a

US$14m

Dec 31 2020US$280kn/a

US$8m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$115m

Mar 31 2020n/an/a

-US$113m

Dec 31 2019US$302kn/a

-US$106m

Sep 30 2019n/an/a

-US$98m

Jun 30 2019n/an/a

-US$85m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$494kn/a

-US$74m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 2.92M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 655.65K ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Chris Posner (54 yo)

3yrs

Görev süresi

US$2,922,469

Tazminat

Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Posner
President3yrsUS$2.92m0.21%
$ 34.2k
Ryan Maynard
Chief Financial Officer2.2yrsUS$1.24m0.015%
$ 2.4k
Derek Chalmers
Co-Founder & Senior Advisor3yrsUS$10.20mVeri yok
Scott Terrillion
Chief Compliance Officer8yrsUS$1.59m0.15%
$ 24.2k
Matthew Murphy
Manager of Investor Relationsno dataVeri yokVeri yok

3.0yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: CARA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Posner
President6.3yrsUS$2.92m0.21%
$ 34.2k
Martin Vogelbaum
Independent Chairman & Lead Independent Director14.3yrsUS$519.99k0.20%
$ 32.6k
Graeme Milligan
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Stanley Watson
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
James Kauer
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Philip Portoghese
Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Jeffrey L. Ives
Independent Director10.3yrsUS$272.49k0.087%
$ 14.2k
Helen Boudreau
Independent Director1.3yrsUS$376.01k0%
$ 0
Susan Shiff
Independent Director4.4yrsUS$262.49k0.094%
$ 15.3k
Lisa von Moltke
Independent Director2yrsUS$254.99k0.059%
$ 9.6k

5.3yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CARA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).